Parse Biosciences Expands Global Access to Israel
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"The past year has represented a considerable leap forward for Parse, with demand growing significantly for our Evercode single cell sequencing solutions," noted Parse CEO and co-founder Alex Rosenberg, Ph.D. "Partnering with a premier distributor in the Middle East positions us well in the region for continued growth."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SEATTLE -- Businesswire -- Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced an agreement with Israel-based Ornat Biochemicals and Laboratory Equipment to extend Parse’s reach in the Middle East.
“The past year has represented a considerable leap forward for Parse, with demand growing significantly for our Evercode single cell sequencing solutions,” noted Parse CEO and co-founder Alex Rosenberg, Ph.D. “Partnering with a premier distributor in the Middle East positions us well in the region for continued growth.”
Parse’s agreement with Ornat will give researchers in Israel access to its full single cell portfolio, including Evercode™ Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, and the Parse Biosciences data analysis solution. The agreement bolsters Parse’s plan to offer its products in key international markets.
“Parse is accelerating the pace of single cell research with its Evercode technology. We're elated to partner with them to introduce this state of the art technology to the thriving biotech community in Israel,” said Ornat CEO, Eyal Lev.
About Parse Biosciences
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
With technology developed at The University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $50 million in capital and is now used by nearly 1,000 customers across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Gene Capture, and a data analysis solution.
Parse Biosciences is based in Seattle’s vibrant South Lake Union district, where it recently opened a 34,000 square foot headquarters and state-of-the-art laboratory. To learn more, please visit https://www.parsebiosciences.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005438/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Parse Biosciences
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- ‘발전기술컨퍼런스 2024’ 12월 6일 대전 DCC에서 개최 - 뉴스와이어
- 농심, 신라면 툼바 출시 두 달만에 1100만 개 판매 - 뉴스와이어
- 이니스프리, 2024 그린 홀리데이 에디션 ‘조이풀 홀리데이 온 디아일’ 리미티드 에디션 출시 -
- 작곡가 박수정 ‘가타부타 歌打副打’ 작곡발표회 개최 - 뉴스와이어
- LG에너지솔루션, 미국 베어로보틱스에 원통형 배터리 단독 공급 - 뉴스와이어
- 서울대 공대 광공학 및 양자전자연구실, VR·AR 디바이스에 최적화된 카메라 초소형화 기술 개발 -
- 투썸플레이스, 한정판 ‘조니워커 블루라벨’ 프리미엄 위스키 케이크 론칭하고 자사 앱 통한
- OATC CRO센터, 피부 및 모발 건강기능식품 효력 검정부터 인허가까지 원스톱 서비스 제공… 큰 호
- 한-이탈리아 수교 140주년 기념, 이탈리아 ‘모자이크’의 2000년 역사를 담아낸 미디어아트 전시
- 프리뉴, 드론 ‘아크 S3’ 굿디자인 어워드 은상 수상 - 뉴스와이어